1 / 34

E speranza I . C abral, MD S ecretary of H ealth Keynote Address at The 3rd MeTA Philippines Forum

“. . . n ow is the time to stop butting heads and start linking arms. It is not impossible to work out a united plan that will be acceptable for all, and in the end will benefit those who need it most.”. E speranza I . C abral, MD S ecretary of H ealth Keynote Address at

zohar
Download Presentation

E speranza I . C abral, MD S ecretary of H ealth Keynote Address at The 3rd MeTA Philippines Forum

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. “. . . now is the time to stop butting heads and start linking arms. It is not impossible to work out a united plan that will be acceptable for all, and in the end will benefit those who need it most.” Esperanza I. Cabral, MD Secretary of Health Keynote Address at The 3rd MeTA Philippines Forum

  2. TRANSPARENCY IN SELECTION of ESSENTIAL MEDICINES FOR THE PHILIPPINE NATIONAL DRUG FORMULARY (PNDF) Nelia P. Cortes-Maramba, M.D. Professor Emeritus Department of Pharmacology & Toxicology College of Medicine, UP Manila Member, National Formulary Committee

  3. Legal Basis 1. Republic Act No. 6675 – GENERICS ACT of 1988 (13 September) An Act to Promote, Require and Ensure the Production of an Adequate Supply, Distribution, Use and Acceptance of Drugs and Medicines Identified by their Generic Names. Prescribed that it is the policy of the State to “ensure the adequate supply of drugs with generic names at the lowest possible cost”

  4. Sec. 4 The Use of Generic Terminology for Essential Drugs and Promotional Incentives a) In the promotion of the generic names for pharmaceutical products, special consideration shall be given to drugs and medicines which are included in the Essential Drugs List to be prepared within one hundred eighty days (180) from approval of this Act and updated quarterly by the Department of Health on the basis of health conditions obtaining in the Philippines as well as on internationally accepted criteria.

  5. Sec 3 Definition of Terms (7) “Essential Drugs List” or “National Drug Formulary” – it shall consist of core list and complementary list (8) “Core list” is a list of drugs that meets the health care needs of the majority of the population. (9) “Complementary List” is a list of alternative drugs used when there is no response to the core essential drug or when there is hypersensitivity reaction to the core essential drug or when for one reason or another, the core essential drug cannot be given.

  6. PROCESS of FORMULATING THE PNDF • consultative and participative process through • regular meetings among members of NFC • series of deliberation meetings with different panels of experts from • Medical schools • Philippine Medical Association • Various specialty and subspecialty societies • Government and private hospitals • inputs from pharmaceutical companies • recommendations of other stockholders

  7. PNDF Volume 1 Essential Medicines list 7th Edition (2008) • major step towards rational use of medicines • medicines selection based on public health relevance, evidence of efficacy and safety, quality and comparative cost-effectiveness

  8. NationalList of Essential Medicines • Subset of FDA registered medicines divided according to different levels of care for higher quality of care, better management of medicines (improved quality control, more cost-effective use of health resources) and ensures regular supply of essential medicines resulting in • real health gain • Increased confidence on the health system

  9. Primary Care Medicines – 68 medicines • List of medicines intended for use in the Rural Health Units • To meet the immediate health needs of majority of the population for commonly encountered ailments all over the country. • Generally safe and do not require special expertise and equipment for proper use. • Two categories • For use by All RHUs (N=30 medicines) • For RHUs with Physicians and other health workers (N=68 medicines)

  10. Classificacions of Drug as Vital (V), Essential (E) and less essential (L) based on the following criteria: 1. frequency of occurrence of target conditions • 2. severity of target conditions • 3. therapeutic effects of the drug (curative, symptomatic relief, etc) • 4. cost of therapy • Classification is useful in prioritizing procurement of medicines especially in resource-poor areas • Dynamic list of medicines with periodic review and updating in the light of new developments and experiences and prevailing health needs of our population

  11. GENERAL GUIDELINES FOR ESTABLISHING THE PHILIPPINE NATIONAL DRUG FORMULARY Drug selection must be based on the following • Relevance to disease – indicated in the treatment of prevalent diseases • Efficacy and safety – based on adequate pharmacologic studies especially among Filipinos (Expanded Phase II clinical trials and/or additional Phase III studies) • Quality – must meet adequate quality control standard including stability and when necessary bioavailability.

  12. General guidelines (Cont’d) - compliance with WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce – product manufactured in accordance with CGMP and records whether or not the product has been approved for marketing in the country of origin. 4. Cost of treatment regimen 5. Appropriateness to the capability of health workers at different levels of health care. 6. Local health problems 7. Benefit/Risk ratio

  13. General guidelines (Cont’d) • 8. Preferential factors for evaluating therapeutically equivalent drugs • 8.1 most thoroughly investigated – beneficial properties and limitations • 8.2 clinical utility for the treatment of more than one condition or disease • 8.3 most favorable pharmacokinetic properties for improved compliance and minimize risk in pathophysiological states • 8.4 dosage form that is easy to dispense or easily or safely administered to patient • 8.5 greater acceptability by most patients • 8.6 favorable stability under anticipated local conditions for which storage facilities exist

  14. General guidelines (Cont’d) • 8.7 existence of local reliable manufacturing facilities for its production • 9. Single Formulations preferred. Fixed ratio combinations are acceptable when • 9.1 value of concomitant use of more than one drug is clinically documented • 9.2 therapeutic benefit of the combination is greater than the sum of the individual components • 9.3 the combination is safer than individual drug • 9.4 cost of combination product is less • 9.5 compliance is improved • 9.6 appropriate drug ratio in the combination is satisfactory for the majority of the population

  15. General guidelines (Cont’d) • 10. Period of Review of Essential Medicines list – yearly • 10.1 New drugs added if with distinct advantage over drugs previously selected • 10.2 Drugs with lower Benefit/Risk ratio should be replaced by those with higher benefit/risk ratio • 11. International NON-PROPRIETARY NAMES (INN) for drugs shall be used

  16. DRUG SELECTION FOR THE PHILIPPINE NATIONAL DRUG FORMULARY No Acceptance safety, proven efficacy, quality and purity? Delist/Deny Registration Yes No Disease/Condition/Indicationfound in the Philippines? Delist/Deny Registration Yes No No High prevalence of disease/condition in the Philippines? Life saving drug Comp list Yes Yes No Two or more therapeutically equivalent drugs? Core List Yes No Favorable benefit / risk ratio? Further Review Yes No Thoroughly investigate / extensive clinical experience? Comp. List Yes No Favorable pharmacokientic properties? Comp. List Yes No Stable under anticipated local conditions? (Accelerated and long term stability) Comp. List Yes No Cost-effective and/or reliable local manufacturing facilities? Comp. List Yes Core List

  17. CRITERIA FOR INCLUSION AND DELETION OF DRUGS FROM THE PHILIPPINE NATIONAL DRUG FORMULARY In addition to the guidelines as stated previously the National Formulary Committee considered the following criteria for including additional drugs: 1. The drug is needed for the prevention and treatment of conditions not already covered in the existing list; 2. The drug is more effective and/or less toxic than a drug listed for the same indication; 3. The drug is at least as effective and safe and of lower cost than the drug listed for the same indication; and 4. The drug is deemed essential for a specific DOH health program/project.

  18. Criteria for Inclusion/Deletion (Cont’d) • On the other hand, the following criteria were applied for deleting a drug from the list: • A more effective or equally effective but less toxic drug becomes available; • In the light of further knowledge, the therapeutic efficacy of the drug is found to be unsatisfactory or questionable; • Toxicity/Suspected toxicity or potential for abuse or dangerous interactions prove to outweigh its therapeutic value; • The drug has fallen into disuse and is no longer available; • The drug is no longer deemed cost-effective to other therapies; and • The drug is fixed dose combination which does not satisfy the requirements of A.O. 96 s, 1990.

  19. ANNEX A PROCESS ALGORITHM FOR INCLUSION / DELETION OF PNDF DRUGS Part 1 RVIEW OF CURRENT PNDF DRUGS Check BFAD registry Has the drug been withdrawn from the market due to safety reason?A Yes Delete No Conduct systematic literature reviewB Yes Is there a new strong evidence of Unfavorable risk: benefit?C Mark for deletion No Consider for deliberation w/ resource persons Is additional good evidence of acceptable safety, proven efficacy, quality and purity presented during deliberations?D Yes Retain the drug No Consider for deletion if there are better drugs in terms of efficacy, safety and cost

  20. ANNEX B REVIEW OF NEW DRUGS FOR POTENTIAL INCLUSION Check BFAD registry Is it officially registered w/ BFAD & marketed in the Philippines No Do not include Yes Is the drug needed for the prevention & treatment of conditions not covered in the formulary? Yes Is the drug under monitored release? No Conduct systematic literature reviewB Do not include Is there a good evidence of favorable risk: benefit? C No Do not include Yes Yes Is there any additional strong evidence that confirms unfavorable risk: benefit from interested parties? D2 Do not include Mark for possible inclusion No Yes Is there a safer and more cost- effective, therapeutically equivalent drug available? Do not include No Include the drug

  21. ANNEX C EVIDENCE TABLE Drug : *group means with standard deviations may be reported if the data are continuous

  22. Systematic Literature Review Process • Clinical Question: Is Drug x a safe and efficacious drug for condition Y? • Comprehensive Search: MEDLINE, HERDIN, COCHRANE, EMBASE – through the NATIONAL DRUG INFORMATION CENTER based in UP Manila • Critical Appraisal of abstracts/full text to verify claims (RCT quality, level of evidence) • Examine similarities and differences of findings across studies may perform META-ANALYSIS. • Independent search submitted by National Drug Information Center (NDIC)

  23. LEVELS OF EVIDENCE (Evidence Based Medicine or EBM) • Level A- STRONG Several relevant high quality scientific studies and results are convergent • Level B – MODERATE At least one high quality study and several adequate studies • Level C – LIMITED At least one adequate study • Level D – WEAK OR NO Adequate Study Expert Panel evaluation – does not fulfill criteria of scientific evidence

  24. Drugs listed by WHO requiring in vivo bioequivalence studies based on the WHO Model List of Essential Medicines which are immediate- release, solid, oral dosage forms • Antimicrobials (9) • cefixime 400 mg • Clofazimine 100 mg • dapsone 100 mg • erythromycin stearate and ethyl succinate 250 mg • rifampicin300 mg and rifampicin FDC with otheranti-TB medicine • sulfamethoxazole 400 mg + trimethoprim 80 mg • sulfazalazine 500 mg • Trimethoprim 200 mg

  25. Antiparasitics (9) • albendazole 400 mg • artemether 20 mg + lumefantrine 120 mg • diloxanide furoate 500 mg • griseofulvin 250 mg • ivermectin 6 mg • mefloquine hydrochloride 250 mg • praziquantel 600 mg • pyrimethamine 25 mg • Sulfadoxine 500 mg + pyrimethamine 25 mg

  26. Cont’d Bioequivalence Studies • Anticancer/Immune – response modifyers (5) • azathioprine 500mg • cyclosporine 25 mg • etoposide 100 mg • mercaptopurine 50 mg • tamoxifen citrate 200 mg • HIV/AIDS Medicines (5) • Endenavir sulfate 400 mg • Nelfinavir mesilate 250 mg • Neviraprine 200 mg • Itonavir 100 mg • Saquinavir 200 mg

  27. OTHERS • Acetazolamide 250 mg • Carbamazepine 200 mg • Furosemide 40 mg • Glibenclamide 5 mg • Haloperidol 2 mg • Iopanoic acid 500 mg • Mifepristone 200 mg • Nifedipine 10 mg • Retinolpalmitate 10 mg (200,000 IU) • Spironolactone 25 mg • Verapamil 80 mg • Added by NFC – Phenytoin sodium • Theophylline anhydrous

  28. Primary Medical Care Drugs • For all Rural Health Units (RHUs) • For RHU & Staffed by Physicians and other Health Workers • Characteristics of Drugs Included

  29. PHILIPPINE NATIONAL DRUG FORMULARY Vol 1, 7th EDITION 2008 No. of Sections of Therapeutic Categories = 22 No. of Active Ingredients = 627 Core list = 350 Complementary List = 277 No. of pharmaceutical products added = 45 No. of pharmaceutical products deleted = 32 No. of pharmaceutical products not available in the market but considered essential (*) = 64 No. of new drugs under Monitored Release = 38 No. of Dangerous Drugs (A1) = 19 (Internationally controlled)

  30. PHILIPPINE NATIONAL DRUG FORMULARY Vol 1, 7th EDITION 2008 (Con’t) No. of Controlled Precursors and Essential Chemicals (A2) = 3 No. of medicines requiring specific expertise, diagnostic precision, or special equipment for proper use (1) = 155 No. of medicines with limited indications or narrow spectrum of activity (2) = 136 No. of antibiotics in the PNDF to be used only in hospitals with DOH accredited Antimicrobial Resistance Surveillance Program (ARSP) (3) = 6 No. of list B medicines = 40 No. of medicinal plant products registered with BFAD (*) = 5

  31. Thank you!

  32. “. . . now is the time to stop butting heads and start linking arms. It is not impossible to work out a united plan that will be acceptable for all, and in the end will benefit those who need it most.” Esperanza I. Cabral, MD Secretary of Health Keynote Address at The 3rd MeTA Philippines Forum

More Related